Rinvoq Clinical Prior Authorization begins March 3

Rinvoq Clinical Prior Authorization begins March 3

FirstCare will implement the Rinvoq (upadacitinib) clinical prior authorization criteria on March 3, 2020. All clinical edit criteria can be found here. New Rinvoq criteria will be included within the existing Cytokine and CAM Antagonists criteria guide.

Rinvoq is a Janus Kinase inhibitor for treatment of adults with moderate-to-severe active rheumatoid arthritis who have not responded adequately, or are intolerant, to methotrexate. The Texas DUR Board approved the criteria at the Oct. 2019 meeting.

Send to a Friend

* Required field

Captcha The math problem above is intended to reduce spam.